

Publisher: John Wiley & Sons Inc
E-ISSN: 1476-5381|172|15|3861-3874
ISSN: 0007-1188
Source: BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol.172, Iss.15, 2015-08, pp. : 3861-3874
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Background and PurposeDespite the increasing importance of biomarkers as predictors of drug effects, toxicology protocols continue to rely on the experimental evidence of adverse events (AEs) as a basis for establishing the link between indicators of safety and drug exposure. Furthermore, biomarkers may facilitate the translation of findings from animals to humans. Combined with a model‐based approach, biomarker data have the potential to predict long‐term effects arising from prolonged drug exposure. Here, we used naproxen as a paradigm to explore the feasibility of a biomarker‐guided approach for the prediction of long‐term AEs in humans.Experimental ApproachAn experimental toxicology protocol was set up for evaluating the effects of naproxen in rats, in which four active doses were tested (7.5, 15, 40 and 80 mg·kg−1). In addition to AE monitoring and histology, a few blood samples were also collected for the assessment of drug exposure, TXB2 and PGE2 levels. Non‐linear mixed effects modelling was used to analyse the data and identify covariate factors on the incidence and severity of AEs.Key ResultsModelling results showed that besides drug exposure, maximum PGE2 inhibition and treatment duration were also predictors of gastrointestinal ulceration. Although PGE2 levels were clearly linked to the incidence rates, it appeared that ulceration severity is better predicted by measures of drug exposure.Conclusions and ImplicationsThese results show that the use of a model‐based approach provides the opportunity to integrate pharmacokinetics, pharmacodynamics and toxicity data, enabling optimization of the design, analysis and interpretation of toxicology experiments.
Related content


Long-Term Efficacy and Safety Profile of Lanthanum Carbonate: Results for up to 6 Years of Treatment
Nephron Clin Pract, Vol. 110, Iss. 1, 2008-07 ,pp. :


Long-Term Renal Safety Profile of Ibandronate 6 mg Infused over 15 Minutes
Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. :


CANCER, Vol. 119, Iss. 20, 2013-10 ,pp. :


By Brinkman Sylvia Abu-Hanna Ameen Jonge Evert Keizer Nicolette
Intensive Care Medicine, Vol. 39, Iss. 11, 2013-11 ,pp. :